Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Duchenne Muscular Dystrophy (DMD) Therapeutics market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Duchenne Muscular Dystrophy (DMD) Therapeutics market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Duchenne Muscular Dystrophy (DMD) Therapeutics products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Duchenne Muscular Dystrophy (DMD) Therapeutics market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Duchenne Muscular Dystrophy (DMD) Therapeutics development has been the leading industry trend of Duchenne Muscular Dystrophy (DMD) Therapeutics market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
EXONDYS,Emflaza,Translarna, Other |
| By Application Outlook |
Hospitals,Clinics,Home Care, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Sarepta Therapeutics,PTC Therapeutics,Pfizer,Bristol-Myers Squibb,Italfarmaco,Santhera Pharmaceuticals,... |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Sarepta Therapeutics
- PTC Therapeutics
- Pfizer
- Bristol-Myers Squibb
- Italfarmaco
- Santhera Pharmaceuticals
- ...
Duchenne Muscular Dystrophy (DMD) Therapeutics Market, By Type
- EXONDYS
- Emflaza
- Translarna
- Other
Duchenne Muscular Dystrophy (DMD) Therapeutics Market, By Application
- Hospitals
- Clinics
- Home Care
- Other
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Chapter 1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Definition
1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Status and Outlook (2014-2027)
1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Region (2014-2027)
1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2014-2027)
1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Application (2014-2027)
1.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Sales Channel (2014-2027)
1.7 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics (COVID-19 Impacts)
1.7.1 Market Drivers/Opportunities
1.7.2 Market Challenges/Risks
1.7.3 Market News (Mergers/Acquisitions/Expansion)
1.7.4 COVID-19 Impacts on Current Market
1.7.5 Post-Strategies of COVID-19 Outbreak
Chapter 2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Player
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Player (2017-2019)
2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Player (2017-2019)
2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Average Price by Player (2017-2019)
2.4 Players Competition Situation & Trends
2.5 Conclusion of Segment by Player
Chapter 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Type
3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type
3.1.1 EXONDYS
3.1.2 Emflaza
3.1.3 Translarna
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Type (2014-2019)
3.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Type (2014-2019)
3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Average Price by Type (2014-2019)
3.5 Leading Players of Duchenne Muscular Dystrophy (DMD) Therapeutics by Type in 2019
3.6 Conclusion of Segment by Type
Chapter 4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Application
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Home Care
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Application (2014-2019)
4.3 Leading Consumers of Duchenne Muscular Dystrophy (DMD) Therapeutics by Application in 2019
4.4 Conclusion of Segment by Application
Chapter 5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Sales Channel
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Sales Channel
5.1.1 Direct Channel
5.1.2 Distribution Channel
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Sales Channel (2014-2019)
5.3 Leading Distributors/Dealers of Duchenne Muscular Dystrophy (DMD) Therapeutics by Sales Channel in 2019
5.4 Conclusion of Segment by Sales Channel
Chapter 6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment Analysis by Region
6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR by Region (2014-2027)
6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales and Market Share by Region (2014-2019)
6.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Region (2014-2019)
6.4 North America
6.4.1 North America Market by Country
6.4.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type
6.4.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application
6.4.4 United States
6.4.5 Canada
6.4.6 Mexico
6.5 Europe
6.5.1 Europe Market by Country
6.5.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type
6.5.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application
6.5.4 Germany
6.5.5 UK
6.5.6 France
6.5.7 Italy
6.5.8 Russia
6.5.9 Spain
6.6 Asia-Pacific
6.6.1 Asia-Pacific Market by Country
6.6.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type
6.6.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application
6.6.4 China
6.6.5 Japan
6.6.6 Korea
6.6.7 India
6.6.8 Southeast Asia
6.6.9 Australia
6.7 South America
6.7.1 South America Market by Country
6.7.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type
6.7.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application
6.7.4 Brazil
6.7.5 Argentina
6.7.6 Colombia
6.8 Middle East & Africa
6.8.1 Middle East & Africa Market by Country
6.8.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type
6.8.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application
6.8.4 UAE
6.8.5 Saudi Arabia
6.8.6 South Africa
6.9 Conclusion of Segment by Region
Chapter 7 Profile of Leading Duchenne Muscular Dystrophy (DMD) Therapeutics Players
7.1 Sarepta Therapeutics
7.1.1 Company Snapshot
7.1.2 Product/Service Offered
7.1.3 Business Performance (Sales, Price, Revenue, Gross Margin and Market Share)
7.1.4 COVID-19 Impact on Sarepta Therapeutics
7.2 PTC Therapeutics
7.3 Pfizer
7.4 Bristol-Myers Squibb
7.5 Italfarmaco
7.6 Santhera Pharmaceuticals
Chapter 8 Upstream and Downstream Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics
8.1 Industrial Chain of Duchenne Muscular Dystrophy (DMD) Therapeutics
8.2 Upstream of Duchenne Muscular Dystrophy (DMD) Therapeutics
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.2.4 Manufacturing Cost Structure
8.2.5 Manufacturing Process
8.3 Downstream of Duchenne Muscular Dystrophy (DMD) Therapeutics
8.3.1 Leading Distributors/Dealers of Duchenne Muscular Dystrophy (DMD) Therapeutics
8.3.2 Leading Consumers of Duchenne Muscular Dystrophy (DMD) Therapeutics
Chapter 9 Development Trend of Duchenne Muscular Dystrophy (DMD) Therapeutics (2020-2027)
9.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (Sales and Revenue) Forecast (2020-2027)
9.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Region (2020-2027)
9.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Type (2020-2027)
9.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Application (2020-2027)
9.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and CAGR Forecast by Sales Channel (2020-2027)
Chapter 10 Appendix
10.1 Research Methodology
10.2 Data Sources
10.3 Disclaimer
10.4 Analysts Certification
